MedTrace Logo

Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5)

NCT05605678 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 108

Last updated 2025-02-07

No results posted yet for this study

Summary

The primary objective of this study is to obtain prospective baseline documentation of annualized bleeding rates (ABRs) and treatment under standard-of-care (SOC) therapy among participants with hemophilia A or B. Participants in the study may be eligible to enroll in future planned interventional studies to be conducted by Sponsor.

Conditions

Interventions

OTHER

No Intervention

This is a non-interventional study.

Sponsors & Collaborators

  • Centessa Pharmaceuticals plc

    collaborator INDUSTRY

  • ApcinteX Ltd

    lead INDUSTRY

Eligibility

Min Age
12 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-09
Primary Completion
2024-11-29
Completion
2024-11-29

Countries

  • United States
  • Armenia
  • Australia
  • Brazil
  • Canada
  • Egypt
  • France
  • Germany
  • India
  • Italy
  • Poland
  • South Africa
  • Spain
  • Taiwan
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05605678 on ClinicalTrials.gov